On August 1, 2017 AIMM Therapeutics BV, an oncology focused developer of novel tumor specific therapeutic antibodies sourced directly from elite responders to immune therapy or from immunized animals, reported that it has entered into an exclusive license and option agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) regarding a series of AIMM’s tumor specific antibodies directed against an undisclosed target expressed on many different tumor types (Press release, AIMM Therapeutics, AUG 1, 2017, View Source [SID1234521097]). In addition, MSD has an exclusive option on a second series of AIMM’s tumor specific antibodies directed against a different tumor target.

Under the terms of the agreement between AIMM and MSD, through a subsidiary, MSD will make an undisclosed upfront payment and future success-based payments. MSD will be responsible for development, manufacturing and commercialization. Additional details were not disclosed.

“We are excited that MSD, as a leader in the field of immuno-oncology, recognizes the unique synergy and clinical potential offered by AIMM’s tumor specific antibodies in combination with KEYTRUDA (pembrolizumab) for cancer patients who have limited or no responses to checkpoint inhibitors alone” said Jan de Vries, AIMM’s CEO.